Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors.
Antibodies, Monoclonal
/ metabolism
Cell Separation
Collagenases
/ metabolism
DNA Barcoding, Taxonomic
Deoxyribonuclease I
/ metabolism
Flow Cytometry
Humans
Immunophenotyping
/ methods
Leukocyte Common Antigens
/ immunology
Lymphocytes
/ physiology
Myeloid Cells
/ physiology
Neoplasms
/ diagnosis
Palladium
/ metabolism
Single-Cell Analysis
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
07
2018
revised:
12
11
2018
accepted:
21
11
2018
entrez:
20
3
2019
pubmed:
20
3
2019
medline:
27
6
2019
Statut:
epublish
Résumé
Monitoring immune responses to solid cancers may be a better prognostic tool than conventional staging criteria, and it can also serve as an important criterion for the selection of individualized therapy. Multiparametric phenotyping by mass cytometry extended possibilities for immunoprofiling. However, careful optimization of each step of such method is necessary for obtaining reliable results. Also, with respect to procedure length and costs, sample preparation, staining, and storage should be optimized. Here, we designed a panel of 31 antibodies which allows for identification of several subpopulations of lymphoid and myeloid cells in a solid tumor and peripheral blood simultaneously. For sample preparation, disaggregation of tumor tissue with two different collagenases combined with DNase I was compared, and removal of dead or tumor cells by magnetic separation was evaluated. Two possible procedures of barcoding for single-tube staining of several samples were examined. While the palladium-based barcoding affected the stability of several antigens, the staining with two differently labeled CD45 antibodies was suitable for cells isolated from a patient's blood and tumor. The storage of samples in the intercalation solution for up to two weeks did not influence results of the analysis, which allowed the measurement of samples collected within this interval on the same day. This procedure optimized on samples from patients with head and neck squamous cell carcinoma enabled identification of various immune cells including rare subpopulations.
Identifiants
pubmed: 30886872
doi: 10.1155/2019/6705949
pmc: PMC6388349
doi:
Substances chimiques
Antibodies, Monoclonal
0
Palladium
5TWQ1V240M
Deoxyribonuclease I
EC 3.1.21.1
Leukocyte Common Antigens
EC 3.1.3.48
Collagenases
EC 3.4.24.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6705949Références
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Clin Exp Immunol. 2011 Jan;163(1):33-49
pubmed: 20939860
Oncoimmunology. 2012 May 1;1(3):346-350
pubmed: 22737611
Nat Biotechnol. 2012 Sep;30(9):858-67
pubmed: 22902532
J Transl Med. 2013 Mar 03;11:54
pubmed: 23452415
PLoS One. 2014 Oct 16;9(10):e110138
pubmed: 25329048
J Immunol. 2015 Feb 15;194(4):2022-31
pubmed: 25609839
Nat Protoc. 2015 Feb;10(2):316-33
pubmed: 25612231
Cytometry A. 2015 Apr;87(4):369-74
pubmed: 25645694
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Oncotarget. 2015 Sep 29;6(29):27832-46
pubmed: 26337837
Cytometry A. 2016 May;89(5):491-7
pubmed: 27018769
J Immunother. 2016 May;39(4):160-70
pubmed: 27070447
Cell. 2016 May 5;165(4):780-91
pubmed: 27153492
Immunotargets Ther. 2014 Dec 04;3:151-65
pubmed: 27471706
Cytometry B Clin Cytom. 2017 Jan;92(1):68-78
pubmed: 27598832
Cancers (Basel). 2016 Nov 24;8(12):
pubmed: 27886124
Curr Protoc Mol Biol. 2017 Apr 3;118:25C.1.1-25C.1.23
pubmed: 28369679
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618